title: [Treatment of the spastic drop foot with botulinum toxin type A in adult patients].
abstract: Spastic drop foot can be managed by physical measures, local pharmacological agents, oral anti-spastic drugs and surgical procedures. Recent studies have documented the clear effect of botulinum toxin type A (BTX-A) in the treatment of the spastic drop foot, particularly by reducing the resistance against passive movement and increasing the range of motion. Functional benefit and pain reduction have also been observed. The use of BTX-A is safe and free of serious side effects. Individual realistic treatment goals must be defined by the rehabilitation team before the treatment. Possible purposes of the treatment are the achievement of a straight foot to allow weight bearing or application of an orthosis and to reduce the premature activation of the calf muscles during gait. Other treatment goals are the facilitation of nursing care, as well as physical and occupational therapy. BTX-A injections can reduce pain, and prevent pressure ulcers or surgical interventions. Early physiotherapy or occupational therapy may increase the treatment effect of BTX-A. Close cooperation between the neurologist, physiotherapist, occupational therapist, nursing staff and other multidisciplinary rehabilitation team members is essential to maximize the benefit for the patients.
authors.affiliation: Klinische Abteilung für Neurologische Rehabilitation, Universitätsklinik für Neurologie, Wien, Osterreich. bernhard.voller@akh-wien.ac.at
authors.forename: B
authors.initials: B
authors.lastname: Voller
authors.forename: D
authors.initials: D
authors.lastname: Földy
authors.forename: H
authors.initials: H
authors.lastname: Hefter
authors.forename: E
authors.initials: E
authors.lastname: Auff
authors.forename: P
authors.initials: P
authors.lastname: Schnider
mesh_terms: D000328:Adult; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004576:Electromyography; D005528:Foot / Q000503:physiopathology; D020233:Gait Disorders, Neurologic / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology / Q000534:rehabilitation; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009788:Occupational Therapy; D010146:Pain / Q000517:prevention & control; D010348:Patient Care Team; D026741:Physical Therapy Modalities; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D016059:Range of Motion, Articular; D012449:Safety; D020521:Stroke / Q000150:complications / Q000503:physiopathology; D014034:Toes / Q000503:physiopathology
chemical_list: D009465:Neuromuscular Agents; D010919:Placebos; D019274:Botulinum Toxins, Type A